Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XORTX Therapeutics Inc. V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc is a clinical-stage biotechnology company. The company focused on developing drug therapies for orphan diseases like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes.


Recent & Breaking News (TSXV:XRTX)

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

GlobeNewswire 12 days ago

XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

GlobeNewswire January 3, 2023

XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study

GlobeNewswire December 19, 2022

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

GlobeNewswire December 8, 2022

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

GlobeNewswire November 28, 2022

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire November 25, 2022

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

GlobeNewswire November 16, 2022

XORTX Presents New Proof of Concept Data at American Society of Nephrology

GlobeNewswire November 3, 2022

XORTX Announces Participation at Upcoming Investor Conferences

GlobeNewswire November 3, 2022

XORTX Receives Further No Objection Letter from Health Canada

GlobeNewswire October 26, 2022

XORTX Sponsored American Society of Nephrology Study Abstract Available Online

GlobeNewswire October 25, 2022

XORTX (TSXV:XRTX) closes US$5M public offering

John Ballem  October 11, 2022

XORTX Announces Closing of US$5 Million Public Offering

GlobeNewswire October 7, 2022

XORTX (TSXV:XRTX) announces US$5M public offering

John Ballem  October 4, 2022

XORTX Announces US$5 Million Public Offering

GlobeNewswire October 4, 2022

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

GlobeNewswire September 19, 2022

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology - Kidney Week 2022

GlobeNewswire September 1, 2022

XORTX (TSXV:XRTX) oral drug yields positive results

Caroline Egan  August 22, 2022

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

GlobeNewswire August 22, 2022

XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

GlobeNewswire August 4, 2022